# IAP4 Rec'd PCT/PTO 12 DEC 2005

PATENT ATTORNEY'S DOCKET NUMBER P51379

# TRANSMITTAL LETTER TO THE U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US) - CONCERNING A FILING UNDER 35 U.S.C 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/US2003/035588

06 November 2003

06 November 2002

TITLE OF INVENTION CHEMICAL COMPOUNDS

APPLICANT(S) FOR DO/US

Jerry Leroy ADAMS, Deborah L. BRYAN, Jiri KASPAREC, Francis David KING, Andrew Kenneth TAKLE, David Matthew WILSON and Steven Neal GOODMAN

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450

ATTENTION: DO/US

### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date December 12, 2005 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV687882550US addressed to the: Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, Va 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

20462

CUSTOMER NUMBER

# IAP4 Rec'd PCT/PTO 12 DEC 2009

Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV S-93)		ATTORNEY'S DOCKET NUMBER P51379			
TRANSMITTAL LETTER ' DESIGNATED / ELECTI CONCERNING A FILIN	U.S. APPLICATION NO. (IEknown, see 37 C.F.R. 1.5)				
INTERNATIONAL APPLICATION NO. PCT/US2003/035588	INTERNATIONAL FILING DATE 06 November 2003	PRIORITY DATE CLAIMED 06 November 2002			
TITLE OF INVENTION CHEMICAL COMPOUNDS					
APPLICANT(S) FOR DO/EO/US Jerry Leroy ADAMS, Debora		C, Francis David KING, Andrew			
Applicant herewith submits to the Uother information:	Inited States Designated/Elected Off	fice (DO/EO/US) the following items and			
<ol> <li>[] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[x] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> </ol>					
<ol> <li>[x] The US has been elected (Article 31).</li> <li>[] A copy of the International Application as filed (35 U.S.C. 371(c)(2))         <ul> <li>a. [] is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [] has been transmitted by the International Bureau.</li> <li>c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> </ol>					
6. [] A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
<ul> <li>7. [] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</li> <li>a. [] are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [] have been transmitted by the International Bureau.</li> <li>c. [] have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. [] have not been made and will not be made.</li> </ul>					
8. [] A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).					
9. [] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
<ul> <li>Items 11. to 16. below concern other document(s) or information included:</li> <li>11. [] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</li> <li>12. [] An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</li> <li>13. [] A FIRST preliminary amendment. (Add claim to priority via Preliminary Amendment).</li> <li>14. [x] A SECOND or SUBSEQUENT preliminary amendment.</li> <li>15. [] A substitute specification.</li> </ul>					
<ul> <li>16. [] A change of power of attorney and/or address letter.</li> <li>17. [] An Abstract on a separate sheet of paper.</li> <li>18. [] Copy of Form PCT/DO/EO/905.</li> </ul>					
Diskette, Notice to Comp	on: Sequence Listing, Statement to Soly with Requirements for Patent Appnd/or Amino Acid Sequence Disclost	plications			

US APPLICATION NO. (if known see 37 CFR 1.50) 10/533,832		- /	INTERNATIONAL APPLICATION NO. PCT/US2003/035588		ATTORNEYS DOCKET NO. P51379	
	lowing fees are submitted	:		CALCULATIONS	PTO USE ONLY	
(x )	one month extension	•••••	\$ 110			
()	two months extension	n	\$ 430			
()	three months extension	three months extension \$ 980				
()	four months extension					
	(not beyond statutory time period) \$1,530					
()	fifth month extension	1	\$2,080			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$0.00				
Surcharge of \$1 months from th	130.00 for furnishing the ce earliest claimed priority	oath or declaration landate (37 CFR 1.492	ater than o 20 o 30 2(e)).	\$0.00		
Claims		Number Extra	Rate			
Total claims	- 20 =	0	0 x \$50.00	\$0.00		
Independent claims	- 3 =	0	0 x \$200.00	\$0.00		
Multiple dependent claims (if applicable) + \$300.00			\$0.00			
	7	TOTAL OF ABOV	E CALCULATIONS =	\$0.00	ļ	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$				
SUBTOTAL =			\$0.00			
Processing fee of \$130.00 for furnishing the English translation later than o 20 o 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +		\$				
0 20 0 50 Mon		TOT	AL NATIONAL FEE =	\$0.00		
				Amount to be	\$	

_	A check in the amount of \$	to cover the above fees is enclosed.

b. E Please charge my Deposit Account No. 19-2570 in the amount of \$0.00 to cover the above fees.

A duplicate copy of this sheet is enclosed.

c. E The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.

d. E General authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application. (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**GLAXOSMITHKLINE** 

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5929

Facsimile (610) 270-5090

SIGNATURE

James C. Kellerman

refunded charged

NAME

43,708

REGISTRATION NO.

n:\jck\cases\p51379\natl stage 2nd submission.doc



## United States Patent and TRADEMARK OFFICE

alling the HKI INF

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

P51379

10/533,832

Jerry Leroy Adams

INTERNATIONAL APPLICATION NO.

PCT/US03/35588

I.A. FILING DATE

PRIORITY DATE

11/06/2003

11/06/2002

20462 SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939

**CONFIRMATION NO. 6108 371 FORMALITIES LETTER** \*OC000000017506504\*

Date Mailed: 11/23/2005

#### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

#### **BARBARA A CAMPBELL**

Telephone: (703) 308-9140 EXT 217

### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/533,832	PCT/US03/35588	P51379

FORM PCT/DO/EO/922 (371 Formalities Notice)

Page 2 of 2